Fig. 6: SB-therapy alleviates experimental AR.
From: Glutaminolysis is required in maintaining immune regulatory functions in B cells
a A schematic of AR mouse model preparation. b–k AR mice were treated with NS (saline) or SB or SBi (both SB and AS101, an inhibitor of IL-10) in nasal instillation (AS101 = 1 mg/ml; SB = 1 mg/ml) daily for 1 week. Scatter dot plots show AR symptoms (nasal scratches, sneezing, and nasal discharges; b–d), Mcp1 and EPX (e, f) in nasal secretions, specific IgE (sIgE), Th2 cytokines and IL-10 in nasal tissue protein extracts (g–k). l–n Single cells were isolated from the nasal mucosal tissues, and analyzed by RT-qPCR, western blotting and FACS. l B cells were isolated from the single cells by cell sorting. Immunoblots show ASCT2 protein, boxplots show the integrated density of immunoblots or ASCT2 mRNA levels in B cells. m, n Gated FACS plots show eosinophil (Eo) counts and mast cell counts; scatter plots show Eo frequency and mast cell frequency. MCC mast cell chymase. The data are presented as mean ± SD; each dot presents data obtained from one mouse. **p < 0.01, ***p < 0.001 (ANOVA followed by the Bonferroni post hoc test), compared with the NS-treated AR group. NC naive control mice (no treatment). Each group consists of six mice. Each experiment was performed three times (two mice each time).
